- Home
- » Tags
- » Lexicon Pharmaceuticals
Top View
- MED-Project Participating Drug Companies - King County Washington, March 2020
- Brookline Brief
- The End Is Nigh for Mylan, but How Different Will the New Company
- Paul E. Callinan, Et Al. V. Lexicon Pharmaceuticals, Inc., Et Al. 19-CV
- Third Quarter Report
- Active Labelers Run Date : Aug 26, 2021
- Changes in Weight Associated with Telotristat Ethyl in the Treatment of Carcinoid Syndrome
- View Annual Report
- 2021 Medicines in Development: Health Equity
- Brookline Brief
- 20200915 MED-Project Participant List.Xlsx
- CY 2017 CDER Drug and Biologic Calendar Year Priority Approvals As of December 31, 2017
- Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome Matthew H
- Ultra Financials Schedule of Portfolio Investments May 31, 2021 See
- LEXICON PHARMACEUTICALS 2013 ANNUAL REPORT ToOurShareholders
- Registered Drug Distribution Agents, Manufacturers Wholesalers As of 2/19/21
- Rebateable Manufacturers
- Labelers Numeric
- Manufacturer's W/Start/End Dates and Sc Ind Appendix 1
- Brookline Brief
- Please Note, These Are the Actual Video-Recorded Proceedings from the Live CME Event and May Include the Use of Trade Names and Other Raw, Unedited Content
- Holdings As of June 30, 2021
- 05/13/2021 Provider Subsystem Healthcare and Family Services Run Time: 20:39:26 Report Id 2794D052 Page: 01
- Lexicon Pharmaceuticals Enters Into Agreement with Tersera Therapeutics LLC for Xermelo
- Attendee List